Actively Recruiting
Study of Autologous Hematopoietic Stem Cell Transplantation With CD19-CART Therapy for Adults Aged 18 to 65 With High-risk Acute Lymphoblastic Leukemia
Led by Institute of Hematology & Blood Diseases Hospital, China · Updated on 2024-09-23
20
Participants Needed
1
Research Sites
104 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the combination of autologous hematopoietic stem cell transplantation and CD19-CART therapy for adults with high-risk acute B-lymphoblastic leukemia. The study aims to observe the effectiveness and side effects of this treatment regimen and assess its safety and efficacy in managing this type of leukemia. The treatment involves first performing autologous hematopoietic stem cell transplantation, followed by transfusion of autologous CD19-CAR T cells seven days after the transplantation. This approach is being tested as a single experimental group without randomization or masking. Participants will be monitored for up to two years after transplantation. Researchers will evaluate outcomes including relapse rate, non-relapse mortality, progression-free survival, overall survival rate, and incidence of infection. Safety and treatment effects will be closely observed throughout this period.
CONDITIONS
Brief Title
Autologous Hematopoietic Stem Cell Transplantation Combined With CD19-CART Treatment of Adult High-risk Acute Lymphoblastic Leukemia
Research Team
E
erlie EL Jiang
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
